Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05ZGW
|
|||
| Former ID |
DIB002398
|
|||
| Drug Name |
DPI-201-106
|
|||
| Synonyms |
4-{3-[4-(Diphenylmethyl)piperazin-1-yl]-2-hydroxypropoxy}-1h-indole-2-carbonitrile; Dpi 201-106; 97730-95-5; SDZ-201106; CHEMBL314639; SDZ-201 106 (+/-); 4-{3-[4-(diphenylmethyl)piperazin-1-yl]-2-hydroxypropoxy}-1h-indole-2-carbonitrile; (+-)-4-(3-(4-(Diphenylmethyl)-1-piperazinyl)-2-hydroxypropoxy)-1H-indole-2-carbonitrile; 1H-Indole-2-carbonitrile, 4-(3-(4-(diphenylmethyl)-1-piperazinyl)-2-hydroxypropoxy-, (+-)-; 4(3-(4-Diphenylmethylpiperazine-1-yl)-2-hydroxypropoxy)-1H-indol-2-carbonitrile; CBiol_001886; DPI-201106; 4-(3-(4-benzhydrylpiperazin-1-yl)-2-hydroxypropoxy)-1H-indole-2-carbonitrile
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cardiovascular disease [ICD-11: BA00-BE2Z; ICD-10: I00-I99] | Terminated | [1] | |
| Company |
Novartis AG
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H30N4O2
|
|||
| Canonical SMILES |
C1CN(CCN1CC(COC2=CC=CC3=C2C=C(N3)C#N)O)C(C4=CC=CC=C4)C5=CC=CC=C5
|
|||
| InChI |
1S/C29H30N4O2/c30-19-24-18-26-27(31-24)12-7-13-28(26)35-21-25(34)20-32-14-16-33(17-15-32)29(22-8-3-1-4-9-22)23-10-5-2-6-11-23/h1-13,18,25,29,31,34H,14-17,20-21H2
|
|||
| InChIKey |
BYBYHCOEAFHGJL-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 97730-95-5
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:110175
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor beta-2 (ADRB2) | Target Info | Inhibitor | [2] |
| Sodium channel unspecific (NaC) | Target Info | Modulator | [3] | |
| KEGG Pathway | Dopaminergic synapse | |||
| Calcium signaling pathway | ||||
| cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Endocytosis | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Salivary secretion | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Beta2 adrenergic receptor signaling pathway | ||||
| Pathway Interaction Database | Arf6 trafficking events | |||
| Arf6 signaling events | ||||
| Reactome | Interaction between L1 and Ankyrins | |||
| Adrenoceptors | ||||
| G alpha (s) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Vitamin D Receptor Pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000134) | |||
| REF 2 | Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. Bioorg Med Chem Lett. 2008 Oct 15;18(20):5391-5. | |||
| REF 3 | Interaction between DPI 201-106 enantiomers at the cardiac sodium channel. Mol Pharmacol. 1990 Jan;37(1):17-24. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.